ClinicalTrials.Veeva

Menu

Neuromuscular Characterisation in Late Adolescent and Adult Cystinosis Patients (Cystinose)

A

Assistance Publique - Hôpitaux de Paris

Status

Completed

Conditions

Cystinosis

Study type

Observational

Funder types

Other

Identifiers

NCT05545774
2022-A01649-34 (Registry Identifier)
APHP220694

Details and patient eligibility

About

The primary objective of the study is to evaluate the change in motor function of patients with cystinosis.

The secondary objectives of the study:

  • assessment of the respiratory function;
  • assessment of the muscle function;
  • assessment of swallowing disorders;
  • assessment radiologically of the muscular efficiency;
  • assessment of lean mass / fat mass ratio;
  • assessment of sleeping disorders;
  • annual assessment of evolution of above functions.

All patients will be examined by experienced neuromuscular specialist (Pr Pascal Laforêt) and pulmonologist specialized in neuromuscular disorders (Pr Hélène Prigent). All evaluations will be performed in Raymond-Poincaré hospital (Teaching hospital of Assistance Publique - Hopitaux de Paris (APHP) and University of Paris-Saclay) neuromuscular center, coordinated by Pr Pascal Laforêt.

Full description

This is a monocentric study. The enrollment will be performed as routine care in the department of neurology - neuromuscular center of Raymond Poincaré hospital (APHP).

Patients with cystinosis will be consecutively invited to participate in the study until 20 patients are included. This will avoid selection bias if any. For eligible non included patients, a specific non-identifying registry will be set-up with a very restricted number of variables indicative of disease severity at baseline, allowing for a comparison of included and non-included patients.

Participating cystinosis patients will be proposed to attend a one-day hospitalization. Evaluations will be performed during stable state upon baseline and during a follow-up visit 12 months later.

The study expected duration is 30 months with 18 months for patients' inclusion and 12 month-follow-up.

Enrollment

20 patients

Sex

All

Ages

16+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients aged ≥ 16 years;
  • Genetically confirmed diagnosis of cystinosis;
  • Presenting motor deficiency of at least one muscle;
  • Covered by health insurance.

Exclusion criteria

  • Patient refusal;
  • Foreign patients under AME health schema;
  • Patients under legal protection;
  • Pregnancy or breast-feeding.

Trial contacts and locations

2

Loading...

Central trial contact

Pascal Laforêt, MD, PhD; Hélène Prigent, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems